Compass Minerals Q3 2026 slides show debt progress amid margin pressure

Compass Minerals shares sank 18.56% to $24.46 after reporting an adjusted loss of $0.14/share vs a $0.06 consensus (-$0.08 miss), even though revenue was $215.3M (slightly up ~0.3% YoY) and modestly above the $205.46M expectation. The salt segment drove the miss with Adjusted EBITDA down 15% to $38.9M and margin contracting 520 bps to 22.4% on higher per-unit production/distribution costs, while Plant Nutrition delivered a 32% Adjusted EBITDA jump to $15.0M (margin +1,450 bps to 39.9%). On a positive note, the company reduced total debt 13% to $716.6M and net debt 11% to $660.3M, improving net leverage to 2.8x from 4.3x, but investors remained focused on persistent salt margin pressure and potential tariff exposure.

Analysis

The market is punishing the quality of earnings, not the balance sheet. That distinction matters: CMP’s equity is still largely a weather-and-logistics levered claim on salt margins, but the deleveraging profile means near-term downside should increasingly be capped by credit stabilization rather than solvency fear. The immediate selloff looks more like multiple compression on a disappointing cost trajectory than a permanent impairment of franchise value.

Over the next 1-3 months, the real catalyst is the winter booking/pricing cycle and whether management can turn higher sticker prices into cleaner EBITDA conversion. If fuel and truck capacity stay tight, smaller regional salt players without CMP’s depot footprint and water access should feel more pain, but if the upcoming winter normalizes after a strong prior season, highway volumes can roll over quickly and overwhelm pricing gains. That makes the stock less about one quarter and more about whether the cost base is structurally resetting higher.

The contrarian risk is that investors may be treating Plant Nutrition as a re-rating catalyst when it is still too small to offset salt cyclicality at the consolidated level. The more important 6-18 month question is whether current EBITDA is closer to a peak than a trough: if pricing has to do the heavy lifting while volumes normalize, today’s leverage improvement could still coexist with a lower mid-cycle equity value. The thesis is falsified if fiscal 2027 guidance shows stable salt EBITDA margins despite normal weather and no further cost creep.

Key Decisions for Investors

• Tactical long CMP only on post-earnings stabilization: buy on a hold above roughly $23.50 for 2-3 sessions, with a stop below $21.75 and a 1-3 month target of $28-$30 if the gap-down is exhausted.
• If CMP rebounds into the $27-$28 area before fiscal 2027 guidance, fade the move with a Nov/Jan $28/$22 put spread; catalyst is winter normalization and cost inflation, not the current quarter.
• Prefer CMP credit over CMP equity on continued deleveraging: senior paper is a better risk-adjusted way to express the balance-sheet repair while the 2030 maturity wall stays distant.
• Set an alert for fiscal 2027 guidance and winter booking metrics; if salt EBITDA margin stays below the low-20s despite double-digit pricing, the bounce thesis should be abandoned.